The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

• Published in: Journal for immunotherapy of cancer 2016-12, Vol.4 (1), p.92-92, Article 92
• Main Authors: McNeel, Douglas G., Bander, Neil H., Beer, Tomasz M., Drake, Charles G., Fong, Lawrence, Harrelson, Stacey, Kantoff, Philip W., Madan, Ravi A., Oh, William K., Peace, David J., Petrylak, Daniel P., Porterfield, Hank, Sartor, Oliver, Shore, Neal D., Slovin, Susan F., Stein, Mark N., Vieweg, Johannes, Gulley, James L.
• Format: Article
• Language: English
• Subjects: Androgen suppression therapy; Androgens; Asymptomatic; Cancer; Cancer therapies; Care and treatment; Clinical medicine; Clinical trials; Cytotoxicity; Dendritic cells; Diagnosis; FDA approval; Guidelines; Immunotherapy; Literature reviews; Lymphocytes; Metastasis; Patients; Position and Guidelines; Position Article and Guidelines; Prostate Cancer; Proteins; Treatment; Tumors; Vaccines
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1186/s40425-016-0198-x

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the management of advanced prostate cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel, including physicians, nurses, and patient advocates, to develop consensus recommendations for the clinical application of immunotherapy for prostate cancer patients. To do so, a systematic literature search was performed to identify high-impact papers from 2006 until 2014 and was further supplemented with literature provided by the panel. Results from the consensus panel voting and discussion as well as the literature review were used to rate supporting evidence and generate recommendations for the use of immunotherapy in prostate cancer patients. Sipuleucel-T, an autologous dendritic cell vaccine, is the first and currently only immunotherapeutic agent approved for the clinical management of metastatic castrate resistant prostate cancer (mCRPC). The consensus panel utilized this model to discuss immunotherapy in the treatment of prostate cancer, issues related to patient selection, monitoring of patients during and post treatment, and sequence/combination with other anti-cancer treatments. Potential immunotherapies emerging from late-stage clinical trials are also discussed. As immunotherapy evolves as a therapeutic option for the treatment of prostate cancer, these recommendations will be updated accordingly.